Dr. Rory Shallis explains new FDA approval for imetelstat @AAMDSIF
Dr. Rory Shallis explains new FDA approval for imetelstat @AAMDSIF
Uploaded June 2024 | Updated September 2026, 16 hours ago
This new therapy is designed for patients with Low-Risk MDS. Dr Shallis explains which patients may see help for their anemia with this treatment as well as manageable side effects.

For more podcast episodes, subscribe or click here: aamds.org/education/podcast-episodes
Dr. Rory Shallis explains new FDA approval for imetelstatExpanded Access to Reblozyl® for Patients with Dr. Guillermo Garcia ManeroPNH and Non Transplant Therapies, from the 2023 New Haven Patient and Family ConferenceWhat is PNH? Webinar recording with Dr. Caroline Piatek2022 Miami Patient and Family Hybrid Conference: PNH with Dr. Damian LaberTransplants for MDS and Severe Aplastic Anemia - 2023 Omaha Patient and Family Hybrid ConferenceThe Future of Clinical Trials for Bone Marrow FailureRecent FDA Approval of Danicopan for patients with PNHTransplant for Severe Aplastic Anemia (Pediatric) - 2022 Memphis Patient & Family ConferencePanel Discussion: Addressing the Gaps in Serving Transplant PatientsPredisposition to MDS (Pediatric) - 2022 Memphis Patient and Family ConferenceBrian Anderson Explains Life, Treatment, and Surviving MDS
AAMDSIF |

Dr. Rory Shallis explains new FDA approval for imetelstat

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER